Goldman Sachs Group: Q4 Earnings Insights

  Goldman Sachs Group (NYSE:GS) reported its Q4 earnings results on Tuesday, January 18, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

 

Goldman Sachs Group (NYSE:GS) reported its Q4 earnings results on Tuesday, January 18, 2022 at 07:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Goldman Sachs Group missed estimated earnings by 7.84%, reporting an EPS of $10.81 versus an estimate of $11.73, which did not surprise analysts.

Revenue was up $898.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $4.82, which was followed by a 3.8% increase in the share price the next day.

Here’s a look at Goldman Sachs Group’s past performance:

 

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate 10.11 10.23 10.22 7.47
EPS Actual 14.93 15.02 18.60 12.08
Revenue Estimate 11.67B 12.17B 12.61B 9.99B
Revenue Actual 13.61B 15.39B 17.70B 11.74B

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Emerson Will Provide Automation Technologies, Software And Analytics For The Ras Laffan Petrochemical Complex In Qatar As Part Of A Consortium With Viasat Energy Services; Will Play Key Role In $6B QatarEnergy And Chevron Phillips Chemical Project

Digital automation technologies will play key role in $6 billion QatarEnergy and Chevron Phillips Chemical project Global software and engineering leader Emerson (NYSE:EMR) will provide automation

EMR

Read More

AstraZeneca, Daiichi Sankyo Say ENHERTU Demonstrated ‘clinically meaningful and durable response’ In Patients With HER2-Positive Advanced Gastric Cancer In DESTINY-Gastric02 Phase II Trial

Detailed results from the positive DESTINY-Gastric02 Phase II trial showed that ENHERTU®(fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibodyDetailed results from the positive DESTINY-Gastric02 Phase II trial showed that ENHERTU®(fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo

AZN